TY - JOUR AU - Das, Satya AU - Johnson, Douglas B. PY - 2019 DA - 2019/11/15 TI - Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors JO - Journal for ImmunoTherapy of Cancer SP - 306 VL - 7 IS - 1 AB - Although immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for patients with many advanced malignancies, only 15–60% of patients respond, leaving a broad swath of patients who do not derive benefit. Identifying biomarkers to optimally identify patients who will benefit from ICIs is a major research focus for the oncology community. Thus far, predictive biomarker research has focused on tumor signatures such as microsatellite instability, programmed death-ligand 1 (PD-L1) expression and tumor mutational burden; clinical biomarkers have been far less studied. One potential clinical biomarker for ICI response in patients is immune-related adverse event (IRAE) onset. SN - 2051-1426 UR - https://doi.org/10.1186/s40425-019-0805-8 DO - 10.1186/s40425-019-0805-8 ID - Das2019 ER -